|
|
Analysis on the Effect and Feasibility of Anti-tuberculosis and Anti-tumor Concurrent Treatment of Pulmonary Tuberculosis Complicated with Lung Cancer |
REN Jianhua, LI Ningxiu, et al |
School of Public Health of Sichuan University, Sichuan Chengdu 610000, China |
|
|
Abstract Objective: To explore the clinical effect and feasibility of anti-tuberculosis and anti-tumor concurrent treatment of pulmonary tuberculosis complicated with lung cancer. Methods: A retrospective analysis of clinical data was carried out in 84 patients with pulmonary tuberculosis complicated with lung cancer admitted to our hospital from March 2010 to June 2015, they were divided into single anti-tuberculosis group (single group for short, n=28), anti-tuberculosis and anti-tumor intermittent treatment group (intermittent group for short, n=26), anti-tuberculosis and anti-tumor concurrent treatment group (concurrent group for short, n=30) according to different treatment modalities, intervention effects of different treatment modalities on pulmonary tuberculosis and lung cancer were compared, flow cytometry was used to determine changes of CD3+, CD4+, CD8+ lymphocytes subsets levels changes before and after the intervention, adverse drug reactions in all groups were recorded, lung cancer quality of life rating form (FACT-L) was used to evaluate improvement of survival treatment of patients before and after the intervention. Results: ①efficacy of anti-tuberculosis in the three group was similar, there was no significant difference (P>0.05); ②there was no significant difference in overall remission rate of anti-tumor in single group and intermittent group (P>0.05), overall remission rate of concurrent group was higher than single group and intermittent group (P>0.05); ③before the treatment, there was no significant difference in lymphocytes subsets indexes in the three groups (P>0.05), after the treatment, CD3+, CD4+, CD8+ of intermittent group and concurrent group were significantly increased compared with the same group before the treatment and single group after the treatment (P<0.05), rising range of all indexes of concurrent group were significantly higher than intermittent group (P<0.05); ④there was no significant difference in quality of life scores before the treatment (P>0.05), 3 and 6 months after the treatment, scores of three groups were significantly increased (P<0.05), rising range of intermittent group was significantly higher than single group (P<0.05), rising range of concurrent group was significantly higher than intermittent group (P<0.05); ⑤gastrointestinal reactions and arrest of bone marrow were mainly adverse reactions of three groups, there was no significant difference in adverse reaction rate (P>0.05). Conclusion: Anti-tuberculosis and anti-tumor concurrent treatment of pulmonary tuberculosis complicated with lung cancer can optimize anti-tumor effect, improve immune function of patients, improve quality of life of patients, and does not increase adverse reaction rate, is safe and feasible.
|
|
|
|
|
[1] 彭秋平,冯青青,柯传庆,等.肺癌合并活动性肺结核临床诊治分析[J].临床肺科杂志,2013,18(7):1289~1291. [2] 肖怀清,杜开齐,张志豪,等.肺结核并肺癌37例临床分析[J].临床误诊误 治,2011,24(3):43~44. [3] 全斌,喻艳林.肺结核合并肺癌的发生机制研究进展[J].山东医药,2015,55(24):104~106. [4] 张培元.肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70~74. [5] 端木宏谨,屠德华,张培元.临床诊疗指南结核病分册[M].北京:人民卫生出版社,2005.126~128. [6] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85~90. [7] 游捷,施志明,张娴静,等.两种国际肺癌患者生活质量量表EORTC QLQ-LC43与FACT-L的比较[J].中国癌症杂志,2009,19(5):364~370. [8] 夏广荣,刘桂梅,靳国华,等.肺癌合并肺结核98例临床分析[J].浙江临床医学,2014,16(9):1357~1358. [9] 段林灿,杨润祥.肿瘤合并结核的治疗[J].中国临床医生杂志,2015,43(11):14~16. [10] 徐丽娟,刘华,李进,等.埃克替尼和吉非替尼一线治疗晚期非小细胞肺癌患者的疗效观察[J].湖南师范大学学报(医学版),2015,12(6):94~96,97. [11] 李山成,张磊,李道堂,等.肺癌合并肺结核39例临床分析[J].山东大学学报(医学版),2014,52(z1):51~52. [12] 高智,蒋之,万轲,等.936例肺结核患者治疗和预后的影响因素分析[J].医学临床研究,2012,29(11):2118~2120. |
[1] |
. [J]. 河北医学, 2017, 23(9): 1583-1584. |
|
|
|
|